Your Article Summary
Morphotek, Inc. Announces a Licensing Deal with Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody
Morphotek, 11/03/09
Morphotek, Inc., a subsidiary of Eisai Inc., that it has entered into a license agreement with Centocor Ortho Biotech Inc. for development and commercialization of an antibody that targets a tumor–associated antigen over–expressed in many solid tumors.
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
ImmunoGen, Inc. Announces Clinical Data Presentations on Three TAP Compounds at Upcoming ASH Annual Meeting and Exposition
ImmunoGen, Inc., 11/25/09
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09
Expanding The Biopharmaceutical Industry's Involvement In Fighting Neglected Diseases
Health Affairs, 11/19/09
Article Search
Sponsor


See Latest Articles


